KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Non-Current Assets (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Other Non-Current Assets data on record, last reported at $5.2 million in Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 14.1% year-over-year to $5.2 million; the TTM value through Sep 2025 reached $5.2 million, up 14.1%, while the annual FY2024 figure was $4.6 million, 0.06% changed from the prior year.
  • Other Non-Current Assets reached $5.2 million in Q3 2025 per NKTR's latest filing, up from $5.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.4 million in Q1 2025 and bottomed at $344000.0 in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $3.2 million, with a median of $2.7 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: crashed 75.65% in 2021, then skyrocketed 549.42% in 2022.
  • A 5-year view of Other Non-Current Assets shows it stood at $2.7 million in 2021, then dropped by 18.19% to $2.2 million in 2022, then surged by 106.86% to $4.6 million in 2023, then grew by 0.06% to $4.6 million in 2024, then increased by 10.95% to $5.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $5.2 million in Q3 2025, $5.0 million in Q2 2025, and $5.4 million in Q1 2025.